private financing

The University of California, San Diego spinout is developing a technology that uses microbial DNA signatures for the early detection of cancer.

Tangen will use the proceeds to scale up manufacturing for its SARS-CoV-2 point-of-care test and accelerate development of a panel test including SARS-CoV-2 targets.

The firm will use the proceeds to support commercialization, regulatory, and product development activities, as well as for general working capital purposes.

The firm will use the proceeds to advance its liquid biopsy early cancer detection assay CancerSEEK in an FDA registrational trial.

The firm added $50 million from Casdin Capital, Danaher Life Sciences, and Agilent Technologies to its $38.5M Series B round announced in May 2019.

BlackRock, the world's largest investment manager, led the round, joined by new investors Deerfield Management and Moore Strategic Ventures as well as existing investors.

Spun out of Insilico Medicine in January, Deep Longevity is developing artificial intelligence-based systems to track aging based on various biomarkers.

Investors in the company, formerly known as Vermillion, have agreed to purchase $11 million in unregistered common stock at a price of $3.50 per share.

Among the brands comprising Calibre are Alpha-Tec Systems, EdgeBio, Microlytic, Molecular Dimensions, and NexTal, which it acquired from Qiagen earlier this year.

The company said it will use the funds in part to continue development of its artificial intelligence-based proteome-wide drug discovery platform.